NL-OMON35269已完成3 期
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C. - N.A.
Schering-Plough0 个研究点目标入组 9 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Subject must be willing to give written informed consent and be able to adhere to the visit schedule.
- •- Subject must have received at least one dose of any study medication (peginterferon, ribavarin, boceprevir or narlaprevir) in a previous SPRI Phase 1, 2 or 3 clinical study in which Boceprevir or Narlaprevir was administered.
排除标准
- •- Concurrent participation in any other clinical study for the treatment of chronic hepatitis C
- •- Retreatment with any antiviral or immunomodulatory drug for chronic hepatitis C after completion
- •of, or discontinuation from, the SPRI Phase 1, 2 or 3 clinical study in which the subject previously
- •participated.
- •- Any condition which in the opinion of the investigator would make the subject unsuitable for
- •enrollment.
研究者
相似试验
进行中（未招募）
1 期
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis Cong-term Follow-up of prior study participantsMedDRA version: 14.0Level: PTClassification code 10019641Term: Hepatic cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2006-006529-25-DESchering-Plough Research Institute1,954
进行中（未招募）
不适用
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis CEUCTR2006-006529-25-PTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.2,800
进行中（未招募）
1 期
ong-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis Cong-term Follow-up of prior study participantsMedDRA version: 8.1Level: LLTClassification code 10019641Term: Hepatic cirrhosisEUCTR2006-006529-25-NLSchering-Plough Research Institute1,954
进行中（未招募）
1 期
ong-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial in which SCH 503034 was Administered for the Treatment of Chronic Hepatitis C. - NDEUCTR2006-006529-25-ITSCHERING-PLOUGH1,954
进行中（未招募）
1 期
ong-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial in which SCH 503034 was Administered for the Treatment of Chronic Hepatitis Cong-term Follow-up of prior study participantsMedDRA version: 8.1 Level: LLT Classification code 10019641 Term: Hepatic cirrhosisEUCTR2006-006529-25-FRSchering-Plough Research Institute1,954